Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.
We treated 191 patients with histologically proved locally advanced stage (T3 or T4) and/or metastatic prostate cancer with a biodegradable depot formulation of a luteinizing hormone-releasing hormone analogue (Zoladex). After an initial increase in serum testosterone in week 1 of therapy a continuous decrease of testosterone to castrate levels was obtained. With a monthly injection of the luteinizing hormone-releasing hormone analogue 4 patients (2 per cent) experienced a transient increase in bone pain, 1 had ureteral obstruction and 1 suffered paraplegia during the first few weeks of therapy. Over-all objective and subjective responses were similar to those obtained by castration or estrogen therapy. The absence of local and systemic (long-term) side effects proves the validity of this approach for patients with advanced prostatic cancer.
Debruyne
F M
FM
Department of Urology, Sint Radboud University Hospital, Nijmegen, The Netherlands.
Denis
L
L
Lunglmayer
G
G
Mahler
C
C
Newling
D W
DW
Richards
B
B
Robinson
M R
MR
Smith
P H
PH
Weil
E H
EH
Whelan
P
P
D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy*; D004334:Drug Administration Schedule; D017273:Goserelin; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood
D017273:Goserelin; D013739:Testosterone; D002064:Buserelin